08:41 AM EST, 11/29/2024 (MT Newswires) -- Silo Pharma Inc ( SILO ) said Friday it has agreed to collaborate with Kymanox to design and develop a subcutaneous insertion device for SP-26, its ketamine-loaded implant for potential treatment of fibromyalgia and chronic pain.

Financial terms were not disclosed.

Under the agreement, Kymanox will come up with a proof-of-concept design followed by prototype and feasibility testing to determine the best insertion depth for the ketamine implants, the company said.

The company said it is conducting preclinical research into the safety of SP-26 with the aim of meeting US Food and Drug Administration requirements for at-home therapeutic designation.